Biopharma Vical (NASDAQ:VICL) has risen to its highest share price in a year — and with rumors of a buyout offer, it shows no sign of stopping.

Pre-pandemic profits on Sinovac (AMEX:SVA) Vical Incorporated (NASDAQ:VICL), and Dr. Reddy’s Laboratories (NYSE:RDY)?

A more recent addition to my transformational technologies portfolio, Medarex (NASDAQ:MEDX), has scored a huge win. The company, along with Massachusetts Biologic Laboratory, will get $60 million upfront from Merck (NYSE:MRK) for license rights to a monoclonal antibody that apparently cures C. difficile infection. They are eligible for another $165 million in milestones as well as royalties.